BioSpace News Archive

Voyager Therapeutics, Inc., a biotechnology company dedicated to advancing neurogenetic medicines, announced it will report first quarter 2024 financial and operating results after market close on Monday, May 13, 2024.

LSL PHARMA GROUP INC. is pleased to announce that it has entered into a binding Letter of Intent to acquire profitable privately held, Quebec-based competing contract drug manufacturer specialized in the formulation, production, and marketing of natural products .

Foghorn® Therapeutics Inc., a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended March 31, 2024.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication from the Chinese National Intellectual Property Administration, valid through 2035.

Guangzhou-Israel Biotechnology Fund announced that it has invested $10 million in Nectin Therapeutics Ltd. Nectin is a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology treatments.

Eisbach Bio GmbH has announced United States Food and Drug Administration clearance of its investigational new drug application for EIS-12656, a small molecule inhibiting the chromatin helicase ALC1.

Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer

Bristol Myers Squibb announced that the U.S. FDA has accepted the Biologics License Application for the subcutaneous formulation of Opdivo® co-formulated with Halozyme’s proprietary recombinant human hyaluronidase across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy, or in combination with chemotherapy or cabozantinib.

Sonnet BioTherapeutics Holdings, Inc., a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024 at The Plaza Hotel in New York.

SAB Biotherapeutics announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors.